MedTrace Logo

Safety of Cat-PAD in Cat Allergic Subjects

NCT00685711 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2008-08-06

No results posted yet for this study

Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the safety of Cat-PAD administered as increasing single doses.

Conditions

  • Cat Allergy

Interventions

BIOLOGICAL

Cat-PAD

single, escalating dose intradermal and subcutaneous injections of Cat-PAD

Sponsors & Collaborators

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Margitta Worm, MD Professor · Allergy-Centre-Charité

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685711 on ClinicalTrials.gov